DK2158331T3 - Nye polymorfier i ABCB1 i sammenhæng med mangel på klinisk respons over for lægemidler - Google Patents
Nye polymorfier i ABCB1 i sammenhæng med mangel på klinisk respons over for lægemidlerInfo
- Publication number
- DK2158331T3 DK2158331T3 DK08759217T DK08759217T DK2158331T3 DK 2158331 T3 DK2158331 T3 DK 2158331T3 DK 08759217 T DK08759217 T DK 08759217T DK 08759217 T DK08759217 T DK 08759217T DK 2158331 T3 DK2158331 T3 DK 2158331T3
- Authority
- DK
- Denmark
- Prior art keywords
- abcb1
- drugs
- lack
- context
- clinical response
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94333507P | 2007-06-12 | 2007-06-12 | |
| PCT/EP2008/004737 WO2008151803A2 (en) | 2007-06-12 | 2008-06-12 | New polymorphisms in abcb1 associated with a lack of clinical response to medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2158331T3 true DK2158331T3 (da) | 2012-12-17 |
Family
ID=39735268
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12179060T DK2520670T3 (da) | 2007-06-12 | 2008-06-12 | Nye polymorphier i ABCB1 forbundet med en mangel på klinisk respons over for lægemidler |
| DK08759217T DK2158331T3 (da) | 2007-06-12 | 2008-06-12 | Nye polymorfier i ABCB1 i sammenhæng med mangel på klinisk respons over for lægemidler |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12179060T DK2520670T3 (da) | 2007-06-12 | 2008-06-12 | Nye polymorphier i ABCB1 forbundet med en mangel på klinisk respons over for lægemidler |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9115398B2 (da) |
| EP (2) | EP2520670B1 (da) |
| DK (2) | DK2520670T3 (da) |
| ES (2) | ES2394529T3 (da) |
| PL (2) | PL2158331T3 (da) |
| WO (1) | WO2008151803A2 (da) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110016541A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genome editing of sensory-related genes in animals |
| US20110016546A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Porcine genome editing with zinc finger nucleases |
| US20110023153A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in alzheimer's disease |
| US20110023156A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Feline genome editing with zinc finger nucleases |
| US20110023152A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genome editing of cognition related genes in animals |
| US20110023143A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of neurodevelopmental genes in animals |
| US20110023151A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genome editing of abc transporters |
| US20110023158A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Bovine genome editing with zinc finger nucleases |
| US20110023139A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in cardiovascular disease |
| US20110023146A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in secretase-associated disorders |
| US20110030072A1 (en) * | 2008-12-04 | 2011-02-03 | Sigma-Aldrich Co. | Genome editing of immunodeficiency genes in animals |
| US20110023141A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved with parkinson's disease |
| US20110016540A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genome editing of genes associated with trinucleotide repeat expansion disorders in animals |
| US20110023148A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genome editing of addiction-related genes in animals |
| US20110023145A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in autism spectrum disorders |
| US20110016539A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genome editing of neurotransmission-related genes in animals |
| US20110023140A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Rabbit genome editing with zinc finger nucleases |
| US20110023144A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in amyotrophyic lateral sclerosis disease |
| US20110016543A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genomic editing of genes involved in inflammation |
| US20110023147A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of prion disorder-related genes in animals |
| US20110023149A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in tumor suppression in animals |
| US20110023150A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genome editing of genes associated with schizophrenia in animals |
| US20110023154A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Silkworm genome editing with zinc finger nucleases |
| CA2821547A1 (en) * | 2010-12-29 | 2012-07-05 | Sigma-Aldrich Co. Llc | Cells having disrupted expression of proteins involved in adme and toxicology processes |
| WO2012103060A1 (en) * | 2011-01-27 | 2012-08-02 | Glaxo Wellcome Manufacturing Pte Ltd | Method of administration and treatment |
| CN102912003A (zh) * | 2011-08-02 | 2013-02-06 | 广州益善生物技术有限公司 | 一种abcb1基因多态性检测特异性引物和液相芯片 |
| GB201210686D0 (en) * | 2012-06-15 | 2012-08-01 | Holsboermaschmeyer Neurochemie Gmbh | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
| US11694539B2 (en) * | 2020-06-16 | 2023-07-04 | Heartware, Inc. | Notification system for low-level preventative LVAD alerts |
| CN113584160A (zh) * | 2021-06-15 | 2021-11-02 | 湖南菲思特精准医疗科技有限公司 | 一种昂司丹琼代谢标志物检测试剂盒及其检测方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL354034A1 (en) | 1999-07-30 | 2003-12-15 | EPIDAUROS Biotechnologie AktiengesellschaftEPIDAUROS Biotechnologie Aktiengesellschaft | Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DK1756310T3 (da) * | 2004-05-12 | 2013-03-18 | Max Planck Gesellschaft | Fremgangsmåde til at påvise polymorfi i ABCB1-genet associeret med mangel af respons for et CNS-aktivt lægemiddel samt lægemiddel omfattende en ABCB1-inhibitor til anvendelse i behandlingen af CNS-relaterede sygdomme |
-
2008
- 2008-06-12 EP EP20120179060 patent/EP2520670B1/en active Active
- 2008-06-12 DK DK12179060T patent/DK2520670T3/da active
- 2008-06-12 ES ES08759217T patent/ES2394529T3/es active Active
- 2008-06-12 DK DK08759217T patent/DK2158331T3/da active
- 2008-06-12 ES ES12179060T patent/ES2456919T3/es active Active
- 2008-06-12 EP EP08759217A patent/EP2158331B1/en active Active
- 2008-06-12 PL PL08759217T patent/PL2158331T3/pl unknown
- 2008-06-12 PL PL12179060T patent/PL2520670T3/pl unknown
- 2008-06-12 US US12/663,997 patent/US9115398B2/en active Active
- 2008-06-12 WO PCT/EP2008/004737 patent/WO2008151803A2/en active Application Filing
-
2015
- 2015-07-16 US US14/800,848 patent/US9901582B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20100184742A1 (en) | 2010-07-22 |
| ES2456919T3 (es) | 2014-04-24 |
| PL2158331T3 (pl) | 2013-01-31 |
| US9115398B2 (en) | 2015-08-25 |
| WO2008151803A2 (en) | 2008-12-18 |
| DK2520670T3 (da) | 2014-05-26 |
| EP2158331B1 (en) | 2012-08-29 |
| WO2008151803A3 (en) | 2009-02-26 |
| PL2520670T3 (pl) | 2014-07-31 |
| EP2520670A1 (en) | 2012-11-07 |
| EP2520670B1 (en) | 2014-02-26 |
| US9901582B2 (en) | 2018-02-27 |
| EP2158331A2 (en) | 2010-03-03 |
| US20160067262A1 (en) | 2016-03-10 |
| ES2394529T3 (es) | 2013-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2158331T3 (da) | Nye polymorfier i ABCB1 i sammenhæng med mangel på klinisk respons over for lægemidler | |
| CY2020008I2 (el) | Φαρμακοτεχνικες μορφες διστρωματικου δισκιου | |
| LTC2140867I2 (lt) | Farmacinė kompozicija | |
| MA30236B1 (fr) | Nouvelle composition pharmaceutique | |
| DK3470077T3 (da) | Fremgangsmåde til forudsigelse af respons på behandling af sygdomme med farmakologiske chaperoner | |
| EP2561352A4 (en) | GENETIC POLYMORPHISMS ASSOCIATED WITH STATIN RESPONSE AND CARDIOVASCULAR DISEASES, DETECTION METHODS AND USES THEREOF | |
| SMT201700095B (is) | Composizioni farmaceutiche per inalazione | |
| DK2236598T3 (da) | Mikroorganismer til forbedring af helbredet hos individer med lidelser i forbindelse med fordøjelse af gluten | |
| DE06722936T8 (de) | Isomerisation pharmazeutischer zwischenprodukte | |
| BRPI1009324A2 (pt) | compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos | |
| ATE553084T1 (de) | Polycyclische säureverbindungen als crth2- antagonisten und antiallergika | |
| DK2442790T3 (da) | Vandige farmaceutiske sammensætninger, indeholdende borat-polyolkomplekser | |
| FR2948568B1 (fr) | Formulation pharmaceutique | |
| EE201300007A (et) | Kombineeritud ravimkoostis diabeedi ning ainevahetushirete raviks | |
| DK2120884T3 (da) | Farmaceutisk sammensætning | |
| FR2943354B1 (fr) | Procede de preparation d'une composition alcoolique a base de the et applications | |
| DK2391351T3 (da) | Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater | |
| EE201300004A (et) | Kombineeritud ravimkoostis sdame-veresoonkonnaga seotud haiguste v?i seisundite raviks | |
| BR112012003149A2 (pt) | composição farmacêutica | |
| ATE512137T1 (de) | Benzoylpiperidinderivate als doppelmodulatoren des 5-ht2a- und des d3-rezeptors | |
| FI20065456L (fi) | Maitotuotteiden rakenteen parantaminen | |
| IT1402371B1 (it) | Barella smontabile per il soccorso in zone impervie | |
| BRPI1010256A2 (pt) | "aplicações terapêuticas no domínio cardiovascular de derivados de quinazolina diona." | |
| IT1398515B1 (it) | Procedimento migliorato per l'analisi di materiali, particolarmente materiali da costruzione, e dispositivo per realizzare questo procedimento | |
| EP2032748A4 (en) | UTILIZING SERPIN 1 POLYMORPHISMS TO PREDICT THE RESPONSE TO ADMINISTRATION OF ACTIVATED PROTEIN C AND THE RISK OF DEATH |